Gelteq vs Vyome
GELS and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GELS and HIND compare
Vyome scores higher on the StockData Score (1 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GELS | HIND |
|---|---|---|
| Size and price | ||
| Market cap | – | $10.8M |
| Share price | $0.269 | $1.54 |
| Change, 1 year | −73.0% | −68.3% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 1.35 | 1.60 |
| Employees | – | 18 |
| StockData Score | ||
| Total score | 0 | 1 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 83.6× |
| Growth | ||
| Revenue growth (TTM) | – | −67.1% |
| Revenue growth, 5Y average | – | −51.0% |
| Profitability | ||
| Gross margin | 30.3% | 52.7% (better) |
| Operating margin | −3318% (better) | −9190% |
| Net margin | – | −8717% |
| FCF margin | −3335% | – |
| Return on equity | – | −194% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Interest coverage | −2.8× (better) | −285.8× |
| Current ratio | 0.09 | 4.37 (better) |
| Altman Z-score | – | −13.57 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 39.6% |
| Shareholder yield | – | 39.6% |
| Ownership | ||
| Held by institutions | – | 2.0% |
| Held by insiders | 14.0% | 6.8% |
| Short interest, % of float | – | 0.28% |
Go deeper
- GELS stock overview
- GELS income statement
- GELS valuation and score
- HIND stock overview
- HIND income statement
- HIND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.